Overview
RVMD market data
Price History
RVMD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.41 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $34.00 – $194.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $38.5K · P/B 9.44 · P/S 3,325.26.
Company News
Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10thGlobenewswire Inc · Jul 23, 2026, 10:15 PM
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsightGlobenewswire Inc · Jul 23, 2026, 5:15 PM
Revolution Medicines shares are trading higher after Wedbush raised its price target on the stock from $181 to $192.1.Benzinga · Jul 23, 2026, 2:39 PM
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1Benzinga · Jul 23, 2026, 2:23 PM
Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal AdenocarcinomaBenzinga · Jul 22, 2026, 8:10 PM
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236Benzinga · Jul 20, 2026, 10:39 AM
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on ItThe Motley Fool · Jul 17, 2026, 1:15 PM
Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.Globenewswire Inc · Jul 10, 2026, 8:15 PM
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235Benzinga · Jul 9, 2026, 2:15 PM
European Medicines Agency's Human Medicines Committee Initiates Phased Review Of Revolution Medicines' Daraxonrasib To Treat Metastatic Pancreatic CancerBenzinga · Jul 7, 2026, 12:50 PM